These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37093270)

  • 21. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
    Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
    J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.
    Tse JY; Ng HK; Lo KW; Chong EY; Lam PY; Ng EK; Poon WS; Huang DP
    Hum Pathol; 1998 Nov; 29(11):1200-7. PubMed ID: 9824096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma.
    Lou L; Li J; Qin M; Tian X; Guo W; Li Y
    Brain Tumor Pathol; 2023 Jan; 40(1):15-25. PubMed ID: 36550382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
    Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
    J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic analysis of spinal meningiomas: correlation with histopathological grade.
    Driver J; Santagata S; Bi WL; Chi JH
    J Neurosurg Spine; 2023 Dec; 39(6):729-733. PubMed ID: 37728381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of p16
    Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
    J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas].
    Chen MN; Mao Q; Liu YH; Mao BY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Jun; 21(3):277-9. PubMed ID: 15192837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
    Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
    BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational signature of extracranial meningioma metastases and their respective primary tumors.
    Biczok A; Thorsteinsdottir J; Karschnia P; Ruf VC; Tonn JC; Herms J; Schichor C; Dorostkar MM
    Acta Neuropathol Commun; 2023 Jan; 11(1):12. PubMed ID: 36641486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
    Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
    J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
    Pinyol M; Cobo F; Bea S; Jares P; Nayach I; Fernandez PL; Montserrat E; Cardesa A; Campo E
    Blood; 1998 Apr; 91(8):2977-84. PubMed ID: 9531609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.
    Ng HK; Li KK; Chung NY; Chan JY; Poon MF; Wong QH; Kwan JS; Poon WS; Chen H; Chan DT; Shi ZF; Mao Y
    Brain Pathol; 2023 May; 33(3):e13120. PubMed ID: 36167400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas.
    Ferreyra Vega S; Wenger A; Kling T; Olsson Bontell T; Jakola AS; Carén H
    Mod Pathol; 2022 Nov; 35(11):1551-1561. PubMed ID: 35701666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma.
    Peng Y; Chen Y; Song M; Zhang X; Li P; Yu X; Huang Y; Zhang N; Ji L; Xia L; Xia X; Yi X; Tan B; Yang Z
    Mol Oncol; 2022 Apr; 16(8):1746-1760. PubMed ID: 35253368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
    Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
    Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.
    Singh J; Mohan T; Sahu S; Sharma MC; Suri A; Sarkar C; Suri V
    Neurooncol Pract; 2024 Aug; 11(4):464-474. PubMed ID: 39006518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
    Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.